Summary
Jefferies has initiated coverage on Anthem Biosciences with a 'Buy' rating and a target price of Rs 1,050, indicating a potential 20% upside. The brokerage highlights the company's integrated CRDMO model and strong growth prospects, forecasting an 18% revenue CAGR through FY29.